Skip to main content

Supply Chain

By Rene Letourneau | 12:02 pm | September 12, 2012
Based on information examined in its Budget Impact Projections report and the National Economic Impact Survey, supply contracting company Novation predicts supply chain costs will increase by 2.9 percent in 2013.
By Rene Letourneau | 04:02 pm | September 11, 2012
Medical device firm Welch Allyn announced Monday it will reduce its workforce by 10 percent over the next three years in reaction to the 2.3 percent medical device tax slated to begin in January 2013 in accordance with the Affordable Care Act.
By Rene Letourneau | 09:45 am | September 11, 2012
The market for products designed to test for hospital-acquired infections (HAIs) grew 10 percent in 2011 to reach $1.2 billion, according to a new report from healthcare market research firm Kalorama Information.
By Rene Letourneau | 02:15 pm | September 07, 2012
In a report released Thursday, the FDA outlined a four-step plan to better monitor and report on the effectiveness and safety of medical devices.
By Rene Letourneau | 12:11 pm | September 04, 2012
Global medical device company St. Jude Medical, Inc. announced last week that the realignment of its product divisions will result in the loss of 300 jobs.
By Rene Letourneau | 10:11 am | September 04, 2012
Margaret Clapp, RPh, chief of pharmacy at Boston-based Partners HealthCare spoke recently with Healthcare Finance News Editor Rene Letourneau about the biggest challenges currently facing the pharmacy.
By Rene Letourneau | 09:52 am | August 31, 2012
Janssen Pharmaceuticals, Inc., and its parent company Johnson & Johnson agreed Thursday to a multi-state settlement to resolve charges of improper marketing and advertising of the anti-psychotic drugs Risperdal and Invega. The company will pay $181 million to 36 states and the District of Columbia.
By Steff Deschenes | 09:46 am | August 27, 2012
Mergers and acquisitions generally occur because organizations want to become bigger or they want to acquire capabilities that will make them more effective, but no matter what the reasons for the transactions, they aren't simple.
By Rene Letourneau | 12:22 pm | August 22, 2012
Venture capital (VC) funding in the life sciences sector, which includes the biotechnology and medical device industries, decreased 39 percent in dollars and 22 percent in number of deals in Q2 2012 compared with Q2 2011, according to PricewatershouseCoopers' recent MoneyTree report. Many industry analysts think this downward trend is likely to continue.
By Rene Letourneau | 03:17 pm | August 17, 2012
The electrical and magnetic neurostimulation technologies market reached $16.3 billion in 2011 and is expected to grow moderately during the next few years, according to a recent report from life sciences research publisher Kalorama Information.